Ozoralizumab: First Approval

Ozoralizumab (Nanozora (R)), a trivalent anti-tumour necrosis factor alpha (TNF alpha) NANOBODY (R) compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.

Automated summary

Ozoralizumab (Nanozora (R)), a trivalent anti-TNF alpha NANOBODY (R) compound, has gained approval in Japan for the treatment of inadequately managed rheumatoid arthritis. This article provides an overview of the development milestones leading to this approval, including its development by Taisho Pharmaceutical Co. Ltd.